- Home
- CHH vs APGE Comparison
CHH vs APGE Comparison
Compare CHH & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHH | APGE |
|---|---|---|
| Founded | 1939 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | 1997 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CHH | APGE |
|---|---|---|
| Price | $95.32 | $77.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $118.00 | $99.44 |
| AVG Volume (30 Days) | 793.7K | ★ 926.2K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 56.73 | N/A |
| EPS | ★ 8.11 | N/A |
| Revenue | ★ $819,632,000.00 | N/A |
| Revenue This Year | $102.10 | N/A |
| Revenue Next Year | $2.00 | N/A |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $84.04 | $26.20 |
| 52 Week High | $157.86 | $80.99 |
Technical Indicators
Market Signals| Indicator | CHH | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 67.49 |
| Support Level | $93.69 | $73.55 |
| Resistance Level | $98.71 | $80.44 |
| Average True Range (ATR) | 2.73 | 3.14 |
| MACD | 1.06 | -0.47 |
| Stochastic Oscillator | 76.08 | 72.26 |
Price Performance
Historical ComparisonAbout CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.